| |
Placebo group (n = 30)
|
Probiotic group (n = 30)
|
P
1
|
|---|
|
Age (year)
|
61.8 ± 9.8
|
60.7 ± 9.4
|
0.64
|
|
Familial history (%)
|
10 (33.7)
|
11 (36.7)
|
0.78†
|
|
Height (cm)
|
163.2 ± 7.1
|
162.5 ± 7.2
|
0.72
|
|
Weight at study baseline (kg)
|
78.2 ± 11.8
|
80.2 ± 15.3
|
0.57
|
|
Weight at end-of-trial (kg)
|
78.2 ± 12.0
|
80.2 ± 15.3
|
0.56
|
|
Weight change (kg)
|
− 0.03 ± 1.1
|
0.04 ± 1.0
|
0.78
|
|
BMI at study baseline (kg/m2)
|
29.3 ± 4.1
|
30.3 ± 5.2
|
0.42
|
|
BMI at end-of-trial (kg/m2)
|
29.3 ± 4.1
|
30.3 ± 5.2
|
0.41
|
|
BMI change (kg/m2)
|
− 0.01 ± 0.4
|
0.06 ± 0.4
|
0.81
|
|
Smoking (%)
|
3 (10.0)
|
3 (10.0)
|
1.00†
|
|
Aspirin 80 mg (%)
|
30 (100)
|
30 (100)
|
1.00†
|
|
Statin (%)
|
30 (100)
|
30 (100)
|
1.00†
|
|
Insulin therapy (%)
|
8 (26.7)
|
7 (23.3)
|
0.76†
|
|
Antidiabetic drugs (%)
|
|
Monotherpy
|
16 (72.7)
|
17 (70.8)
| |
|
Combination therapy
|
6 (27.3)
|
7 (29.2)
|
0.88†
|
|
Hypertension (%)
|
22 (73.3)
|
23 (76.7)
|
0.76†
|
|
ACEI/ARB drugs (%)
|
30 (100)
|
30 (100)
|
1.00†
|
|
Blocker drugs (%)
|
|
β-blocker
|
28 (93.3)
|
29 (96.7)
| |
|
Calcium channel blocker
|
2 (6.7)
|
1 (3.3)
|
0.55†
|
|
Duration of DM (year)
|
6.8 ± 2.2
|
6.6 ± 1.9
|
0.61
|
|
Duration of CHD (year)
|
9.5 ± 2.2
|
9.3 ± 1.6
|
0.78
|
- Data are means ± SDs
- ACEI Angiontensin converting enzymes inhibitors, ARB Aldosterone receptor blockers, CHD coronary heart disease, DM diabetes mellitus
- 1Obtained from independent t-test
- †Obtained from Pearson Chi square test
